导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.06% | 3113/4773 |
| 近一周 | -2.02% | 3968/5467 |
| 近一月 | -7.34% | 3440/5421 |
| 近一季 | -9.55% | 3039/5238 |
| 近半年 | -4.18% | 2906/4931 |
| 近一年 | -0.27% | 2658/4400 |
| 近两年 | 45.54% | 1626/2954 |
| 近三年 | 27.67% | 1163/2253 |
| 成立以来 | 118.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.37% 3162/4961 |
13.50% 1992/5312 |
- - |
- - |
| 2025 | 22.60% 1955/4813 |
0.01% 2013/3635 |
1.01% 2499/4076 |
21.44% 1793/4524 |
-0.07% 2339/4813 |
| 2024 | 16.75% 771/3463 |
3.19% 613/2808 |
-0.91% 868/3014 |
17.73% 1131/3129 |
-3.02% 2233/3463 |
| 2023 | -11.14% 1372/2656 |
4.62% 904/2280 |
-4.76% 1281/2385 |
-3.69% 971/2515 |
-7.41% 2138/2655 |
| 2022 | -20.83% 994/2207 |
-13.93% 875/1919 |
7.03% 547/2016 |
-15.02% 1197/2113 |
1.14% 1373/2208 |
| 2021 | -8.30% 1049/1822 |
-2.37% 629/1255 |
0.88% 1078/1330 |
-8.25% 1120/1466 |
1.48% 917/1822 |
| 2020 | 27.75% 572/1250 |
-11.98% 865/1028 |
12.17% 696/1067 |
12.19% 402/1164 |
15.33% 218/1184 |
| 2019 | 38.61% 306/1092 |
26.05% 429/754 |
3.20% 58/804 |
0.82% 457/850 |
5.69% 688/918 |
| 2018 | -21.33% 209/834 |
- - |
- - |
- - |
-13.10% 509/691 |
| 2017 | 30.90% 53/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.25% 195/605 |
- - |
- - |
- - |
- - |
| 2015 | -1.31% 262/575 |
- - |
- - |
- - |
- - |
| 2014 | 60.23% 34/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成中证A100ETF VS. 长安沪深300非周期A(740101) |